Deucravacitinib for plaque psoriasis.
出版信息
Aust Prescr. 2024 Dec;47(6):195-196. doi: 10.18773/austprescr.2024.049.
Abstract
摘要
相似文献
1
Deucravacitinib for plaque psoriasis.德卡伐替尼用于斑块状银屑病。
Aust Prescr. 2024 Dec;47(6):195-196. doi: 10.18773/austprescr.2024.049.
2
SOTYKTU (Deucravacitinib 6-mg Tablets)- A New Agent for the Management of Adult Plaque Psoriasis.SOTYKTU（地达西单抗 6 毫克片剂）- 一种用于成人斑块型银屑病治疗的新型药物。
Skinmed. 2023 Aug 28;21(3):192-196. eCollection 2023.
3
Deucravacitinib (Sotyktu) for plaque psoriasis.用于斑块状银屑病的氘可来昔替尼（Sotyktu）。
Med Lett Drugs Ther. 2023 Feb 20;65(1670):29-31. doi: 10.58347/tml.2023.1670b.
4
Deucravacitinib: First Approval.地达西布替尼：首次获批
Drugs. 2022 Nov;82(17):1671-1679. doi: 10.1007/s40265-022-01796-y.
5
The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.酪氨酸激酶2抑制剂氘可来昔替尼治疗斑块状银屑病的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
Front Med (Lausanne). 2023 Sep 29;10:1264667. doi: 10.3389/fmed.2023.1264667. eCollection 2023.
6
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 Trial.口服选择性变构酪氨酸激酶2抑制剂氘可来昔替尼治疗日本斑块状银屑病患者：3期POETYK PSO-4试验疗效与安全性的深入分析
J Dermatol. 2025 Jun;52(6):953-966. doi: 10.1111/1346-8138.17744. Epub 2025 Apr 30.
7
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.德夸鲁单抗（POETYK PSO-2 研究）治疗斑块型银屑病：通俗易懂的总结。
Immunotherapy. 2023 Aug;15(11):787-797. doi: 10.2217/imt-2023-0062. Epub 2023 May 7.
8
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial.氘可来昔替尼，一种口服选择性变构酪氨酸激酶2抑制剂，用于中国大陆、中国台湾和韩国中重度斑块状银屑病患者：一项III期随机临床试验。
Br J Dermatol. 2025 Feb 18;192(3):402-409. doi: 10.1093/bjd/ljae406.
9
Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta-analysis.德瓦鲁单抗治疗中重度斑块型银屑病的安全性和有效性：一项荟萃分析。
Skin Res Technol. 2024 Aug;30(8):e13855. doi: 10.1111/srt.13855.
10
Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.德瓦鲁单抗：首个获 FDA 批准的用于中重度斑块状银屑病的口服 TYK2 抑制剂。
Ann Pharmacother. 2024 Apr;58(4):416-427. doi: 10.1177/10600280231153863. Epub 2023 Jun 21.
本文引用的文献
1
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.氘可来昔替尼改善中度至重度银屑病患者的患者报告结局：3期随机POETYK PSO-1和PSO-2试验结果
Dermatol Ther (Heidelb). 2024 Aug;14(8):2235-2248. doi: 10.1007/s13555-024-01224-x. Epub 2024 Jul 30.
2
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).度普利尤单抗治疗中重度斑块状银屑病：两项 3 期临床试验（POETYK PSO-1 和 PSO-2）汇总的 52 周安全性和耐受性结果。
J Eur Acad Dermatol Venereol. 2024 Aug;38(8):1543-1554. doi: 10.1111/jdv.19925. Epub 2024 Mar 7.
3
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.度鲁特韦治疗斑块状银屑病：III 期 POETYK 试验的 2 年安全性和疗效结果。
Br J Dermatol. 2024 Apr 17;190(5):668-679. doi: 10.1093/bjd/ljae014.
4
Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.德卡伐替尼：一种用于治疗中重度银屑病的新型酪氨酸激酶2抑制剂。
J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165. doi: 10.1177/24755303231201336. Epub 2023 Sep 5.
5
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.德瓦鲁单抗对比安慰剂和阿普米司特治疗中重度斑块状银屑病：为期 52 周、随机、双盲、III 期方案 fOr 评估 TYK2 抑制剂银屑病二次试验的疗效和安全性结果。
J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14.
6
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.德瓦鲁单抗对比安慰剂和阿普米司特治疗中重度斑块型银屑病：来自 52 周、随机、双盲、安慰剂对照 3 期 POETYK PSO-1 试验的疗效和安全性结果。
J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9.
Zotero 插件